8-K: Intelligent Bio Solutions Reports 20% Revenue Growth in Fiscal Q3 2025, Driven by Cartridge Sales

Intelligent Bio Solutions Inc. announced a 20% sequential quarterly revenue increase and a 91% year-over-year gross profit increase for fiscal Q3 2025, fueled by growing cartridge sales and customer acquisition.

Summary

• Intelligent Bio Solutions Inc. (INBS) announced its financial results for the third fiscal quarter ended March 31, 2025.
• The company reported a 20% increase in revenue compared to the previous quarter, reaching $0.73 million.
• Gross profits increased by 91% year-over-year to $341,368.
• Cartridge sales accounted for 58% of total revenue for the nine months ended March 31, 2025.
• The company added 35 new accounts during the quarter, bringing the total active customer base to over 450.
• INBS is expanding its international presence and product readiness through various initiatives, including multilingual upgrades and intellectual property protection.
• The net loss attributable to the Company decreased by $434,141 to $2,543,526 for the three months ended March 31, 2025, compared to the same period in 2024.
• Total cash and cash equivalents on hand as of March 31, 2025, was $2.81 million.
• Shareholders equity as of March 31, 2025, was $4.94 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the reported revenue and gross profit growth, as well as the expansion of the customer base and international presence. However, the company is still operating at a net loss, which tempers the overall positive outlook.

Positives

• The company experienced a significant increase in revenue and gross profit.
• The growth in cartridge sales indicates a strengthening recurring revenue model.
• The expansion of the customer base demonstrates the company's ability to acquire new clients.
• International growth initiatives and multilingual upgrades enhance the company's global scalability.
• The granting of a new U.S. patent strengthens the company's intellectual property portfolio.
• The company's net loss decreased compared to the same period in the previous year.

Negatives

• The company is still operating at a net loss, although it has decreased compared to the previous year.
• Total revenue for the nine months ended March 31, 2025, was $2.21 million compared to $2.38 million for the same period in 2024.

Risks

• The company's ability to successfully develop and commercialize its drug and diagnostic tests is subject to risks and uncertainties.
• Realizing commercial benefits from partnerships and collaborations is not guaranteed.
• Securing regulatory approvals may face challenges and delays.
• The company's cash and cash equivalents decreased from $6.30 million as of June 30, 2024, to $2.81 million as of March 31, 2025.

Future Outlook

The company plans to scale its commercial footprint and international presence ahead of its expected entry into the U.S. market and believes its efforts are laying a strong foundation for long-term, sustainable revenue growth.

Management Comments

• Harry Simeonidis, President and CEO, stated that the company's focus on growing cartridge adoption is strengthening the business fundamentals.
• He also noted a notable reduction in losses this quarter, reflecting ongoing improvements in cost control and operational efficiency.
• Management believes that multilingual functionality across the drug screening system and websites ensures the solution is widely accessible, commercially viable, and ready for broader distribution across international markets.

Industry Context

The company operates in the medical technology sector, specifically focusing on drug screening solutions. The announcement highlights the company's efforts to expand its market presence and improve its product offerings to compete effectively in the industry.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without knowing the specific financial benchmarks for similar companies in the point-of-care drug testing market.
• However, companies like Abbott and Roche offer competing diagnostic solutions, and their growth rates and profitability could be used as a general benchmark.
• The 20% sequential revenue growth is a positive sign, but it's important to compare this to the average growth rate of other companies in the industry to assess its relative performance.
• The increase in gross profit margin suggests improved operational efficiency, which is a key metric for success in the medical technology industry.

Stakeholder Impact

• Shareholders may be encouraged by the revenue and gross profit growth, as well as the company's expansion efforts.
• Employees may benefit from the company's growth and expansion, potentially leading to new opportunities.
• Customers may benefit from the company's improved product offerings and expanded availability.
• Suppliers may see increased demand for their products and services as the company grows.
• Creditors may view the company's improved financial performance as a positive sign.

Next Steps

• The company plans to continue scaling its commercial footprint and international presence.
• INBS intends to further expand into new markets and focus on growing cartridge adoption.
• The company will continue regulatory scoping in Canada, Indonesia, and the Philippines to support long-term expansion strategy.

Key Dates

Keywords

Intelligent Bio Solutions, drug screening, financial results, revenue growth, cartridge sales, gross profit, medical technology, fingerprint drug testing, international expansion